Recursion Pharmaceuticals News - October 15, 2026
Recursion Pharmaceuticals prices $200M offering and reports clinical progress in third quarter 2026
Recursion Pharmaceuticals announced a preliminary third quarter 2026 cash balance of approximately $561 million and the pricing of a $200 million underwritten...
Recursion's Triple-Barrel Announcement Lifts Shares 10% — But Can Clinical Promise Outrun Dilution?
Shares of Recursion Pharmaceuticals surged +10.4% to $4.13 as the AI-driven biotech orchestrated a carefully timed trifecta: updated trial data for two key...
🟢 Recursion Pharmaceuticals is trading 10.43% up today after REC-4881's 47% median polyp-burden reduction
Recursion Pharmaceuticals is trading at $4.13, up 10.43% in live trading, amid October 15 clinical updates. - REC-4881 updates included a 47% median reduction...
🟢 Recursion Pharmaceuticals is trading 5.48% up today amid trial updates and Sanofi's $10 million milestone
Recursion Pharmaceuticals is trading at $3.94, up 5.48%, amid October 15 clinical updates and a Sanofi milestone announcement. - Recursion reported...
🟢 Recursion Pharmaceuticals is trading 5.75% up today with no clear catalyst identified
Recursion Pharmaceuticals is trading 5.75% up at $3.92, with no single cause established for the gain. - On October 15, the company announced positive clinical...
🔴 Recursion Pharmaceuticals is trading 6.2% down in pre-market on October 15, 2026, on rate concerns
Recursion Pharmaceuticals is trading 6.15% down in pre-market at $3.51 on October 15, 2026, as broader market pressure weighs on growth shares. - September...